Phosphorus

AEMPS

Structural macromineral of bone and ATP; pharmaceutical and parenteral forms are potassium, sodium and calcium phosphates

ATC code: A12CX-PHOSPHORUS (Phosphorus (potassium, sodium and calcium phosphates))

Brand names

K-Phos Neutral, Phos-NaK, Multitrace-5

Mechanism of action

Phosphorus in the body exists as phosphate and makes up 1 % of body weight, with 85 % in the skeleton as hydroxyapatite. Metabolic roles: ATP, GTP and other nucleotides, membrane phospholipids, DNA and RNA, cyclic AMP, blood buffering. Phosphate homeostasis is controlled by parathyroid hormone (raises renal excretion), calcitriol (raises intestinal absorption) and FGF23 (raises excretion via 1-alpha-hydroxylase suppression). For hypophosphataemia (below 0.8 mmol/L) oral or intravenous potassium and sodium phosphates are used. Dietary sources include meat, dairy, fish, legumes and whole grains; typical Western diet supplies 1200–1500 mg/day, above the 700 mg RDA.

Indications

Hypophosphataemia (phosphorus deficiency)

First line

Phosphorus preparations are used for confirmed hypophosphataemia: refeeding syndrome in severely undernourished patients, after prolonged fasting, in chronic alcoholism, recovery from diabetic ketoacidosis, oncology with rapid tumour growth, Fanconi syndrome and hypophosphataemic rickets. Strategy: oral phosphates 30–80 mmol/day in moderate hypophosphataemia (0.3–0.8 mmol/L) and IV phosphates 0.08–0.32 mmol/kg every 6 hours in severe forms (below 0.3 mmol/L) with mandatory monitoring of calcium, potassium, magnesium and renal function. Guidelines: ASPEN 2020 and Spanish SENPE 2022. AEMPS registered Phosphate Sandoz with these indications.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Minerals for general health (supplement marketing)

Not recommended

Phosphorus in multi-mineral supplements is marketed for «bone health and energy». In reality a typical Western diet provides 1200–1500 mg/day of phosphorus, twice the 700 mg RDA, and almost all adults exceed requirements. Excess phosphorus from food and supplements is linked to calcium-phosphorus imbalance in chronic kidney disease, worse cardiovascular prognosis in CKD and possible long-term effects on bone mineral density. NIH ODS and do not recommend phosphorus supplements in people without confirmed hypophosphataemia. If phosphorus was bought for «bones» or «energy», consider seeking a second opinion.

Sources

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA

Spanish Medicines Information Centre (CIMA)

Label dated: 09/22/2021

FDA / DailyMed

FDA — DailyMed Drug Labels

Label dated: 02/17/2022

Safety

Contraindications

Hyperphosphataemia (plasma phosphate above 1.45 mmol/L)
Severe renal impairment with eGFR below 30 mL/min/1.73 m² without dialysis
Hypercalcaemia with hypercalciuria (risk of calcium phosphate stones)
Severe dehydration
Acute muscle injury with hyperkalaemia risk (for potassium-containing phosphates)

Serious adverse effects

Acute phosphate nephropathy in patients with CKD or dehydration after sodium phosphate bowel preparation – FDA warning 2008
Hypocalcaemia with tetany and arrhythmia after rapid IV administration
Hyperkalaemia with potassium-containing phosphates in renal impairment
Metastatic calcification of soft tissues and vessels in prolonged hyperphosphataemia

Common adverse effects

Diarrhoea with high-dose oral preparations
Nausea
Abdominal pain
Bloating

PregnancyFDA C

Adequate phosphorus intake in pregnancy is 700 mg/day and is covered by ordinary diet. Phosphorus preparations are used in clinically indicated hypophosphataemia with electrolyte and renal monitoring. IV phosphates are given with calcium and magnesium monitoring to avoid tetany. Phosphate Sandoz SmPC (AEMPS) – use in pregnancy only when clinically required.

Breastfeeding

Phosphorus is normally present in human milk. Therapeutic phosphate preparations do not change infant levels and are used in lactation by clinical indication.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Phosphorus used for?

Phosphorus is evaluated for the following indications with varying evidence strength: Hypophosphataemia (phosphorus deficiency) (evidence tier B), Minerals for general health (supplement marketing) (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Phosphorus?

Common side effects of Phosphorus (≥ 1 in 100): Diarrhoea with high-dose oral preparations, Nausea, Abdominal pain, Bloating. See the Safety section for uncommon and serious reactions.

Is Phosphorus safe during pregnancy?

FDA category C. Adequate phosphorus intake in pregnancy is 700 mg/day and is covered by ordinary diet. Phosphorus preparations are used in clinically indicated hypophosphataemia with electrolyte and renal monitoring. IV phosphates are given with calcium and magnesium monitoring to avoid tetany. Phosphate Sandoz SmPC (AEMPS) – use in pregnancy only when clinically required.

Is Phosphorus compatible with breastfeeding?

Phosphorus is normally present in human milk. Therapeutic phosphate preparations do not change infant levels and are used in lactation by clinical indication.

Who should not take Phosphorus?

Phosphorus is contraindicated in: Hyperphosphataemia (plasma phosphate above 1.45 mmol/L); Severe renal impairment with eGFR below 30 mL/min/1.73 m² without dialysis; Hypercalcaemia with hypercalciuria (risk of calcium phosphate stones); Severe dehydration; Acute muscle injury with hyperkalaemia risk (for potassium-containing phosphates). Full list in the Safety section.

Mechanism of action

Indications

Hypophosphataemia (phosphorus deficiency)

First line

Sources

Safety

Contraindications

Hyperphosphataemia (plasma phosphate above 1.45 mmol/L)
Severe renal impairment with eGFR below 30 mL/min/1.73 m² without dialysis
Hypercalcaemia with hypercalciuria (risk of calcium phosphate stones)
Severe dehydration
Acute muscle injury with hyperkalaemia risk (for potassium-containing phosphates)

Serious adverse effects

Acute phosphate nephropathy in patients with CKD or dehydration after sodium phosphate bowel preparation – FDA warning 2008
Hypocalcaemia with tetany and arrhythmia after rapid IV administration
Hyperkalaemia with potassium-containing phosphates in renal impairment
Metastatic calcification of soft tissues and vessels in prolonged hyperphosphataemia

Common adverse effects

Diarrhoea with high-dose oral preparations
Nausea
Abdominal pain
Bloating

PregnancyFDA C

Breastfeeding

Phosphorus is normally present in human milk. Therapeutic phosphate preparations do not change infant levels and are used in lactation by clinical indication.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Phosphorus used for?

What are the side effects of Phosphorus?

Common side effects of Phosphorus (≥ 1 in 100): Diarrhoea with high-dose oral preparations, Nausea, Abdominal pain, Bloating. See the Safety section for uncommon and serious reactions.

Is Phosphorus safe during pregnancy?

Is Phosphorus compatible with breastfeeding?

Phosphorus is normally present in human milk. Therapeutic phosphate preparations do not change infant levels and are used in lactation by clinical indication.

Who should not take Phosphorus?